Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
This August, management intends to start two late-stage studies, namely REVEAL-1 and REVEAL-2, evaluating two active dosing regimens of VRDN-003 in active and chronic TED, respectively. In both studies, patients will initially receive a high initial dose of 600mg (split into two 300mg injections). Following this dosage, patients will continue with injections of 300mg each. The total number of injections will depend on the treatment regimen – six injections in the four-week regimen and three injections in the eight-week regimen. The primary endpoint of each study will be the proptosis responder rate (at least 2mm improvement in proptosis from baseline) after 24 weeks of treatment. Post this period, the study patients will be followed for another 28 weeks. Viridian intends to enroll around 84 and 126 patients in the REVEAL-1 and REVEAL-2 studies, respectively. Viridian expects to report top-line data from both clinical studies in the first half of 2026. If data from the studies are
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year [Seeking Alpha]Seeking Alpha
- Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $29.00 price target on the stock.MarketBeat
VRDN
Earnings
- 5/8/24 - Beat
VRDN
Sec Filings
- 6/28/24 - Form 4
- 6/28/24 - Form 4
- 6/28/24 - Form 4
- VRDN's page on the SEC website